J Clin Pharmacol Ther. 2025;6(1):JCPT-06-1066 | Open Access
Camila Heredia, Moizza Zia Ul Haq and Navindra Persaud
Background: Medicines with the same molecular structure have similar clinical effects but can have different societal impacts including those related to drug spending and access. This study examined how countries prioritize access to such medicines using national essential medicines lists as a metric.
Methods: In May 2023, we reviewed 158 national essential medicines lists to identify molecularly and clinically equivalent medicine pairs, ... Read more
RESEARCH ARTICLE Updated Mar 26, 2025 PDF
J Clin Pharmacol Ther. 2025;6(1):JCPT-06-1065 | Open Access
Spataro F1*§, Desantis V§2, Di Girolamo A1, Ria R2, Vacca A2 and Solimando AG2
Colchicine is an anti-inflammatory drug essential for treating recurrent pericarditis, gout, and familial Medi-terranean fever. Despite its benefits, hypersensitivity reactions, such as urticaria and angioedema, can limit its use, posing a significant challenge in managing conditions like pericarditis. Desensitization protocols may enable patients with hypersensitivity to safely resume colchicine therapy.
A 30-year-old woman with recurrent pericarditis developed a hypersensitivity reaction, ... Read more
CASE REPORT Updated Jan 06, 2025 PDF
J Clin Pharmacol Ther. 2024;5(3):JCPT-05-1064 | Open Access
Jessica M. Van Laren, James M. Backes and Daniel E. Hilleman
Weight loss drugs are indicated for the optimization of health in obese or overweight patients with comorbidities. Weight loss should lead to improvements in lipids, Hgb A1c, and blood pressure. This review addressed the impact of weight loss achieved with drug therapy and the relative magnitude of changes in cardiometabolic parameters observed in randomized placebo-controlled trials. The magnitude of ... Read more
RESEARCH ARTICLE Updated Dec 13, 2024 PDF
J Clin Pharmacol Ther. 2024;5(3):JCPT-05-1063 | Open Access
Maodi Gong, Hua Shi, Yikun Wu, Yuangao Xu, Guangyi Hong, Wei Chen and Shuxiong Xu
Renal Ischemia-Reperfusion (I/R) injury can cause renal insufficiency, leading to the need for renal replacement therapy in severe cases, placing a substantial burden on patient recovery and life. Mitigating renal I/R injury is a current research focus. Protein kinase C (PKC) isozymes, with PKCβII as the primary isoform in the kidney, are crucial protein kinases. Ferroptosis ... Read more
RESEARCH ARTICLE Updated Dec 02, 2024 PDF
J Clin Pharmacol Ther. 2024;5(3):JCPT-05-1062 | Open Access
Lin Yimin and Hong Qingxia
Purpose: This study aims to investigate the Adverse Drug Event (ADE) signals associated with potassium ion adhesive sodium cyclozirconate using the United States Food and Drug Administration's Adverse Event Reporting System (FAERS), providing insights for its safe clinical application.
Methods: Adverse reactions related to Sodium Zirconium Cyclosilicate (SZC) were retrieved from the FAERS database, covering the period from May 2018 ... Read more
RESEARCH ARTICLE Updated Nov 20, 2024 PDF